Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health

Article

NEW YORK -- Globally, approximately 418 million people are currently infected with hepatitis, and the unrecognized importance, danger, and costs of hepatitis in the 21st century cannot be understated or underestimated, according to Global Hepatitis Strategies, a new report by Kalorama Information.

Paradoxically, despite the obvious crisis, world governments are not taking the necessary steps to contain hepatitis. Yet the incidence and prevalence of hepatitis have begun to rise in certain parts of the global community, and even industrialized nations are lacking hepatitis control policies. Moreover, there is a greater crisis in hepatitis screening, diagnosis, and treatment emerging, particularly in those areas where HIV/AIDS is becoming more prevalent.

Kalorama Information estimates that the theoretical global market for all hepatitis testing products and therapeutics in 2006, assuming that aggressive screening were to be conducted, would be $3.3 trillion, with the western Pacific and southeast Asia showing the greatest need. However, the estimated realistic market potential for the various global regions for 2006, based on their currently reported hepatitis status and pricing structure, fell far short, reaching just $326 million.

"The strategic concept of hepatitis diagnosis and therapy is one of the most insufficiently recognized areas that the healthcare industry has ever seen," notes Kenneth. G. Krul, PhD, the report's author. "Governments, with the exception of a limited few, seem unable or unwilling to devise comprehensive hepatitis containment and prevention policies. In order to cope with the challenges and opportunities of hepatitis diagnostics and therapeutics, companies must think on a global basis, focusing on three points for the development of strategy: potential market, epidemiology and technology."

Global Hepatitis Strategies focuses on the factors that influence policy aspects of hepatitis, the options presented, the factors associated with strategic market development of hepatitis diagnostics and therapeutics, and prospects for the future. The report analyzes strategic market effects of epidemiology, market potential and technology, trends in epidemiology, and social/political attitudes towards hepatitis.

Source: Kalorama Information

   

Recent Videos
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Mark Wiencek, PhD
Rebecca Crapanzano-Sigafoos, DrPH, CIC, AL-CIP, FAPIC
The CDC’s updated hospital respiratory reporting requirement has added new layers of responsibility for infection preventionists. Karen Jones, MPH, RN, CIC, FAPIC, clinical program manager at Wolters Kluwer, breaks down what it means and how IPs can adapt.
Studying for the CIC using a digital tablet and computer (Adobe Stock 335828989 by NIKCOA)
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Cheron Rojo, BS, FCS, CHL,  CER, CFER, CRCST
Matthias Tschoerner, Dr Sc
Standardizing Cleaning and Disinfection
Related Content